• Home
  •  / Seneca Biopharma

Seneca Biopharma

OverviewSuggest Edit

Seneca Biopharma (formerly NeuralStem) is a clinical-stage biopharmaceutical company. The Company's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinsona's Disease. NeuralStem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.

TypePublic
Founded1996
HQGermantown, MD, USMap
Websitesenecabio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)5(-54%)
Revenue (FY, 2020)$13.5 K(-12%)
Share Price (Nov 2019)$1.2 (+7%)
Cybersecurity ratingAMore

Key People/Management at Seneca Biopharma

Kenneth C. Carter

Kenneth C. Carter

Executive Chairman
Cristina Csimma

Cristina Csimma

Director
Matthew Kalnik

Matthew Kalnik

President & Chief Operating Officer
David Recker

David Recker

Chief Medical Officer
Mary Ann Gray

Mary Ann Gray

Director
Thomas Hazel

Thomas Hazel

Senior Vice President, Research
Show more

Seneca Biopharma Office Locations

Seneca Biopharma has offices in Germantown and Rockville
Germantown, MD, US (HQ)
Goldrenrod Building, 20271 Goldenrod Ln #2024
Rockville, MD, US
9700 Great Seneca Hwy
Show all (2)

Seneca Biopharma Financials and Metrics

Seneca Biopharma Revenue

Seneca Biopharma's revenue was reported to be $13.52 k in FY, 2020
USD

Revenue (FY, 2020)

13.5k

Net income (FY, 2020)

(16.3m)

EBIT (FY, 2020)

(10.7m)

Market capitalization (31-Oct-2019)

4.0m

Closing stock price (31-Oct-2019)

1.5

Cash (31-Dec-2020)

10.5m
Seneca Biopharma's current market capitalization is $4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

390.6k407.7k110.0k18.8k10.4k16.2k260.0k260.0k15.4k13.5k

General and administrative expense

5.8m256.0k5.3m9.0m6.5m7.5m5.5m4.6m4.6m8.7m

R&D expense

7.4m6.1m7.1m8.1m12.6m13.2m8.1m4.0m4.1m2.0m

Operating expense total

13.2m6.4m12.4m17.1m19.2m20.7m13.6m8.5m8.6m10.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

103.4k156.3k78.1k170.8k102.5k2.5k2.5k4.2k5.0k5.0k2.9k2.5k2.5k2.5k2.5k2.5k2.5k2.5k2.5k2.5k252.5k2.5k2.5k7.9k2.5k6.0k2.5k

General and administrative expense

1.5m1.1m1.2m821.4k1.3m1.2m1.3m1.7m3.5m1.5m2.0m1.4m1.7m1.8m3.2m1.4m1.3m1.3m1.6m1.2m1.2m1.3m1.2m944.6k971.8k1.3m1.3m1.5m

R&D expense

2.1m2.1m1.4m1.6m1.4m1.7m1.9m1.8m1.6m1.9m2.1m3.2m3.3m3.4m3.1m2.5m3.6m2.9m2.6m1.4m1.2m1.0m897.1k1.5m954.5k825.5k696.9k446.0k

Operating expense total

3.6m3.3m2.6m2.4m2.7m2.9m3.2m3.6m5.1m3.4m4.0m4.6m5.0m5.2m6.2m3.8m4.9m4.2m4.2m2.6m2.4m2.3m2.1m2.5m1.9m2.1m2.0m1.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

2.4m7.4m16.8m12.5m4.7m15.2m6.7m5.8m5.1m10.5m

Accounts Receivable

234.4k3.3k10.0k225.5k37.3k312.8k294.1k21.1k116.3k

Prepaid Expenses

430.4k205.7k255.7k274.1k1.2m402.3k363.3k510.9k1.4m

Inventories

Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

6.1m4.2m5.1m2.5m9.9m12.7m11.2m16.4m18.3m15.2m11.9m13.6m8.6m13.1m7.6m11.1m5.7m11.7m6.4m9.1m9.7m7.1m5.7m4.0m2.3m7.3m10.0m15.8m

Accounts Receivable

234.4k56.9k833.0104.3k56.8k7.5k11.4k24.5k32.8k8.2k18.8k19.2k39.2k5.1k12.7k14.7k5.3k37.5k137.4k478.7k162.0k237.8k169.9k61.2k19.0k16.9k

Prepaid Expenses

300.7k653.9k404.6k234.2k289.8k220.9k156.6k344.0k319.6k196.2k409.1k388.1k904.2k1.3m1.1m705.8k946.9k477.1k239.3k548.8k347.0k343.4k545.2k295.4k256.8k605.3k414.7k390.6k

Current Assets

6.4m4.8m5.8m2.8m10.2m13.5m12.0m17.3m34.1m30.8m27.7m29.2m24.7m19.6m8.7m11.8m6.7m17.2m11.7m14.7m10.2m7.9m6.5m4.5m2.7m8.0m10.5m16.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(12.5m)(10.1m)(19.8m)(22.6m)(20.9m)(21.1m)(15.7m)(4.9m)(8.4m)(16.3m)

Depreciation and Amortization

187.1k211.1k244.7k348.6k345.5k337.5k289.2k185.8k143.9k92.3k

Accounts Payable

888.3k(644.0k)(116.7k)1.4m(1.0m)879.1k(1.5m)(37.0k)(15.7k)(105.0k)

Cash From Operating Activities

(8.1m)(8.5m)(10.6m)(11.7m)(18.9m)(15.6m)(13.4m)(7.7m)(7.3m)(9.0m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(6.8m)(10.0m)(2.5m)(4.8m)(7.4m)(3.6m)(9.8m)(16.5m)(5.9m)(12.7m)(17.1m)(5.1m)(10.5m)(16.1m)(6.6m)(10.5m)(15.7m)(7.6m)(12.2m)(12.4m)(2.1m)(2.8m)(4.6m)(3.1m)(4.6m)(6.3m)(7.6m)(9.5m)

Depreciation and Amortization

85.3k149.5k34.9k76.2k164.2k50.1k100.6k182.0k90.5k177.2k260.2k83.8k167.4k255.4k85.5k177.5k275.1k112.2k180.6k233.6k67.4k114.3k160.5k39.8k77.2k113.7k29.1k57.7k

Accounts Payable

(182.4k)438.6k(189.1k)(694.5k)(342.3k)44.1k(430.3k)(97.1k)184.7k465.6k899.3k(376.0k)(405.1k)(1.3m)1.2m955.2k1.0m(227.6k)(160.7k)(920.6k)293.1k(151.7k)(25.5k)244.3k208.5k340.7k138.6k(279.9k)

Cash From Operating Activities

(4.5m)(6.3m)(2.1m)(4.5m)(6.0m)(2.5m)(5.9m)(8.1m)(2.7m)(5.1m)(8.2m)(4.7m)(9.5m)(15.0m)(3.5m)(7.1m)(11.5m)(4.4m)(7.8m)(11.1m)(1.8m)(4.4m)(6.0m)(1.7m)(3.3m)(5.2m)(1.7m)(3.7m)
show all
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Seneca Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

Seneca Biopharma Online and Social Media Presence

Seneca Biopharma's Trends

Embed Graph

Seneca Biopharma News and Updates

March 23, 2021

Seneca Biopharma Reports 2020 Yearend Results

GERMANTOWN, Md., March 22, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results for the year ended December 31, 2020. Business Highlights...
March 22, 2021

Thinking about buying stock in Support.com, Seneca Biopharma, Hall of Fame Resort & Entertainment, Dyadic International, or Stonemor?

NEW YORK, March 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPRT, SNCA, HOFV, DYAI, and STON. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...
December 24, 2020

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Seneca Biopharma, Inc. - SNCA

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Buildingin New York City, is investigating Seneca Biopharma, Inc. ("Seneca" or the "Company") (SNCA) relating...
December 18, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Seneca Biopharma, Inc.

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seneca Biopharma, Inc. ("Seneca" or the "Company") (NASDAQ: SNCA) in connection with the Company's proposed merger with...
December 15, 2020

Seneca Biopharma Granted 180-Day Extension by NASDAQ to Regain Compliance with Bid Price Rule

GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that it has received written notification from The Nasdaq Stock Market...
May 22, 2020

Seneca Biopharma Announces Pricing of $5 Million Registered Direct Offering Priced At-the-Market

GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced that it has entered into definitive agreements with several...
Show more

 Seneca Biopharma Frequently Asked Questions

  • When was Seneca Biopharma founded?

    Seneca Biopharma was founded in 1996.

  • Who are Seneca Biopharma key executives?

    Seneca Biopharma's key executives are Kenneth C. Carter, Cristina Csimma and Matthew Kalnik.

  • How many employees does Seneca Biopharma have?

    Seneca Biopharma has 5 employees.

  • What is Seneca Biopharma revenue?

    Latest Seneca Biopharma annual revenue is $13.5 k.

  • What is Seneca Biopharma revenue per employee?

    Latest Seneca Biopharma revenue per employee is $2.7 k.

  • Who are Seneca Biopharma competitors?

    Competitors of Seneca Biopharma include InVivo Therapeutics, Pandion Therapeutics and Jnana.

  • Where is Seneca Biopharma headquarters?

    Seneca Biopharma headquarters is located at Goldrenrod Building, 20271 Goldenrod Ln #2024, Germantown.

  • Where are Seneca Biopharma offices?

    Seneca Biopharma has offices in Germantown and Rockville.

  • How many offices does Seneca Biopharma have?

    Seneca Biopharma has 2 offices.